4.6 Article

β-Glucan-Activated Human B Lymphocytes Participate in Innate Immune Responses by Releasing Proinflammatory Cytokines and Stimulating Neutrophil Chemotaxis

期刊

JOURNAL OF IMMUNOLOGY
卷 195, 期 11, 页码 5318-5326

出版社

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1500559

关键词

-

资金

  1. National Institutes of Health [HL112849, HL62150]
  2. Annenberg Foundation

向作者/读者索取更多资源

B lymphocytes play an essential regulatory role in the adaptive immune response through Ab production during infection. A less known function of B lymphocytes is their ability to respond directly to infectious Ags through stimulation of pattern recognition receptors expressed on their surfaces. beta-Glucans are carbohydrates present in the cell wall of many pathogenic fungi that can be detected in the peripheral blood of patients during infection. They have been shown to participate in the innate inflammatory response, as they can directly activate peripheral macrophages and dendritic cells. However, their effect as direct stimulators of B lymphocytes has not been yet fully elucidated. The aim of this study was to examine the molecular mechanisms and cytokine profiles generated following beta-glucan stimulation of B lymphocytes, compared with the well-established TLR-9 agonist CpG oligodeoxynucleotide (CpG), and study the participation of beta-glucan-stimulated B cells in the innate immune response. In this article, we demonstrate that beta-glucan-activated B lymphocytes upregulate proinflammatory cytokines (TNF-alpha, IL-6, and IL-8). Of interest, b-glucan, unlike CpG, had no effect on B lymphocyte proliferation or IgM production. When compared with CpG (TLR9 agonist), beta-glucan-activated cells secreted significantly higher levels of IL-8. Furthermore, IL-8 secretion was partially mediated by Dectin-1 and required SYK, MAPKs, and the transcription factors NF-kappa B and AP-1. Moreover, we observed that conditioned media from beta-glucan-stimulated B lymphocytes elicited neutrophil chemotaxis. These studies suggest that beta-glucan-activated B lymphocytes have an important and novel role in fungal innate immune responses.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cell & Tissue Engineering

Nuclear reprogramming with a non-integrating human RNA virus

Christopher B. Driscoll, Jason M. Tonne, Moustafa El Khatib, Roberto Cattaneo, Yasuhiro Ikeda, Patricia Devaux

STEM CELL RESEARCH & THERAPY (2015)

Article Biotechnology & Applied Microbiology

Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy

Kevin G. Shim, Shane Zaidi, Jill Thompson, Tim Kottke, Laura Evgin, Karishma R. Rajani, Matthew Schuelke, Christopher B. Driscoll, Amanda Huff, Jose S. Pulido, Richard G. Vile

MOLECULAR THERAPY (2017)

Article Biotechnology & Applied Microbiology

Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy

H. V. Reddi, C. B. Driscoll, P. Madde, D. Milosevic, R. M. Hurley, S. J. McDonough, J. Hallanger-Johnson, B. McIver, N. L. Eberhardt

CANCER GENE THERAPY (2013)

Article Oncology

APOBEC3 Mediates Resistance to Oncolytic Viral Therapy

Amanda L. Huff, Phonphimon Wongthida, Timothy Kottke, Jill M. Thompson, Christopher B. Driscoll, Matthew Schuelke, Kevin G. Shim, Reuben S. Harris, Amy Molan, Jose S. Pulido, Peter J. Selby, Kevin J. Harrington, Alan Melcher, Laura Evgin, Richard G. Vile

MOLECULAR THERAPY-ONCOLYTICS (2018)

Article Oncology

Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment

Laura Evgin, Amanda L. Huff, Timothy Kottke, Jill Thompson, Amy M. Molan, Christopher B. Driscoll, Matthew Schuelke, Kevin G. Shim, Phonphimon Wongthida, Elizabeth J. Ilett, Karen Kaluza Smith, Reuben S. Harris, Matt Coffey, Jose S. Pulido, Hardev Pandha, Peter J. Selby, Kevin J. Harrington, Alan Melcher, Richard G. Vile

CANCER IMMUNOLOGY RESEARCH (2019)

Article Oncology

Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity

Matthew R. Schuelke, Phonphimon Wongthida, Jill Thompson, Timothy Kottke, Christopher B. Driscoll, Amanda L. Huff, Kevin G. Shim, Matt Coffey, Jose Pulido, Laura Evgin, Richard G. Vile

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Article Multidisciplinary Sciences

APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy

Christopher B. Driscoll, Matthew R. Schuelke, Timothy Kottke, Jill M. Thompson, Phonphimon Wongthida, Jason M. Tonne, Amanda L. Huff, Amber Miller, Kevin G. Shim, Amy Molan, Cynthia Wetmore, Peter Selby, Adel Samson, Kevin Harrington, Hardev Pandha, Alan Melcher, Jose S. Pulido, Reuben Harris, Laura Evgin, Richard G. Vile

NATURE COMMUNICATIONS (2020)

Article Multidisciplinary Sciences

Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy

Timothy Kottke, Jason Tonne, Laura Evgin, Christopher B. Driscoll, Jacob van Vloten, Victoria A. Jennings, Amanda L. Huff, Brady Zell, Jill M. Thompson, Phonphimon Wongthida, Jose Pulido, Matthew R. Schuelke, Adel Samson, Peter Selby, Elizabeth Ilett, Mark McNiven, Lewis R. Roberts, Mitesh J. Borad, Hardev Pandha, Kevin Harrington, Alan Melcher, Richard G. Vile

Summary: The study shows that tumors escaping oncolytic therapy with VSV-IFN beta express a mutated form of the CSDE1 gene which inhibits viral replication. However, this mutation also generates a neoantigen that can be targeted for immunotherapy against treatment-resistant tumors.

NATURE COMMUNICATIONS (2021)

Article Cell Biology

Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice

Laura Evgin, Tim Kottke, Jason Tonne, Jill Thompson, Amanda L. Huff, Jacob van Vloten, Madelyn Moore, Josefine Michael, Christopher Driscoll, Jose Pulido, Eric Swanson, Richard Kennedy, Matt Coffey, Houra Loghmani, Luis Sanchez-Perez, Gloria Olivier, Kevin Harrington, Hardev Pandha, Alan Melcher, Rosa Maria Diaz, Richard G. Vile

Summary: Combining oncolytic viruses (OVs) and CAR T cell therapy can enhance the efficacy of CAR T cells in the solid tumor microenvironment. Stimulation of the native T cell receptor by viral epitopes can enhance CAR T cell proliferation and antitumor function, leading to prolonged survival.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Article Medicine, Research & Experimental

miRNA-mediated control of exogenous OCT4 during mesenchymal-epithelial transition increases measles vector reprogramming efficiency

Ramya Rallabandi, Brenna Sharp, Conrad Cruz, Qi Wang, Alexis Locsin, Christopher B. Driscoll, Ella Lee, Tim Nelson, Patricia Devaux

Summary: This study investigates the role of exogenous OCT4 in the reprogramming process and proposes a novel approach using miRNA targeting in a viral vector to control vector-induced processes. The results demonstrate that exogenous OCT4 is required only for the initiation of reprogramming and continuous expression of SOX2, KLF4, and c-MYC is necessary for the maturation stage of iPSC. The application of miRNA targeting in a viral vector shows potential for improving the efficiency of reprogramming.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2022)

暂无数据